Sanofi buys US haemophilia treatment firm for $11.6 bn

Breaking News

Sanofi buys US haemophilia treatment firm for $11.6 bn

January 22, 2018 sub EditorEconomy

French pharmaceutical firm Sanofi said Monday it had reached an agreement to purchase US biotech company Bioverativ, which specialises in treatments for haemophilia and rare blood disorders, for $11.6 billion (9.5 billion euros).

► Necessary Cookies Standard

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

None

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

None

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

None

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

None

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31